Phase 1b Study of ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 May 2018
At a glance
- Drugs Apalutamide (Primary) ; Everolimus (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- 01 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 01 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 10 Jun 2017 Biomarkers information updated